Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Zofia Piotrowska, MD

Advertisement

Articles by Zofia Piotrowska, MD

OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC

OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC

ByZofia Piotrowska, MD
April 19th 2022

In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.

EGFR Exon 20 Insertion As A Therapeutic Target in Non-small Cell Lung Cancer

Recap: Targeted Therapies for EGFR Exon 20 Insertion-Positive NSCLC

ByZofia Piotrowska, MD
December 27th 2021

Zofia Piotrowska, MD, discusses potential therapies for patients with EGFR exon 20 insertion-positive non–small cell lung cancer.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on CancerNetwork

    1

    Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines

    2

    AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026

    3

    40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study

    4

    GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations

    5

    42 Intraoperative Frozen Analysis of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy Does Not Provide Additional Surgical Benefit and Increases the Rate of Unnecessary ALND in Clinically Node-Negative Breast Cancer Patients

    • About
    • Advertise
    • CureToday.com
    • OncLive.com
    • OncNursingNews.com
    • TargetedOnc.com
    • Editorial
    • Contact
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us